Abstract: In a model training method, a first set of texts is generated based on a conversation of a first user. The first set of texts indicate a tendency of the first user in response to the conversation. A first score of each text of the first set of texts is determined based on behavior data of the first user. The first score indicates a correlation between the tendency of the first user and a behavior of the first user in response to the conversation. The first set of texts is combined based on the first score of each text, to obtain a plurality of pairs of texts. A first prediction model is trained based on the plurality of pairs of texts.

Abstract: Disclosed herein are minimal arrestin domain containing protein 1 (ARRDC1) constructs, which drive the formation of ARRDC1-mediated microvesicles (ARMMs). These vesicles can be harnessed to package and deliver a variety of molecular cargos such as small molecules, nucleic acids, and proteins. An example of such cargo is the genome editor Cas9.

Abstract: The present disclosure provides a data query method. In the method, a first query result of a first database in response to a first query request is obtained. The first database stores data within a first time window. A second query result of a second database is obtained when the first query result does not meet a preset check condition. The second database stores data within a second time window. A start time of the second time window being after a start time of the first time window. A target query result based on at least one of the first query request and the second query result is generated by processing circuity. An update frequency of the second database is higher than an update frequency of the first database.

Abstract: The present disclosure provides arrestin domain-containing protein 1 (ARRDC1)-mediated microvesicles (ARMMs) modified with Nipah virus (NiV) glycoproteins fused to antibodies or antigen-binding fragments and NiV fusion proteins, and variants thereof. The ARMMs of the present disclosure may be targeted to particular cell types and used to deliver agents (e.g., therapeutic agents) to target cells. Microvesicle-producing cells are also provided by the present disclosure. The present disclosure also provides methods of delivering molecules to target cells using the ARMMs described herein, and methods of treating a patient using any of the ARMMs or microvesicle-producing cells provided herein. Kits comprising any of the ARMMs or microvesicle-producing cells described herein are also provided by the present disclosure.

Abstract: A reaction system for preparing soda ash and a reaction method are provided in the present invention. The reaction system includes: a carbonization tower, a reaction crystallization tower, and a first micro-interface unit. A material outlet is arranged at the bottom of the carbonization tower, and the material outlet is connected to the reaction crystallization tower. The first micro-interface unit includes a first micro-interface generator and a second micro-interface generator, the first micro-interface generator is arranged below the liquid level in the carbonization tower, the second micro-interface generator is arranged above the first micro-interface generator, and a connecting pipe is arranged between the second micro-interface generator and the first micro-interface generator.

Abstract: A reaction system for preparing soda ash and a reaction method are provided in the present invention. The reaction system includes: a carbonization tower, a reaction crystallization tower, and a first micro-interface unit. A material outlet is arranged at the bottom of the carbonization tower, and the material outlet is connected to the reaction crystallization tower. The first micro-interface unit includes a first micro-interface generator and a second micro-interface generator, the first micro-interface generator is arranged below the liquid level in the carbonization tower, the second micro-interface generator is arranged above the first micro-interface generator, and a connecting pipe is arranged between the second micro-interface generator and the first micro-interface generator.

Abstract: A method for sentiment analysis includes that: a feature sequence corresponding to text is obtained, the feature sequence includes encoded features; each encoded feature in the feature sequence is processed by using an attention mechanism, to obtain an attention feature of the text; the attention feature is transferred to a spatial transform feature of the text; an entity attribute of the spatial transform feature is recognized, and sentiment mapping is performed based on the spatial transform feature to obtain a sentiment polarity of the entity attribute.

Abstract: A speech recognition method. The method includes: performing speech activity detection on speech data to obtain multiple speech segments; determining, for each of the speech segments, a number of speakers involved in the each of the speech segments; for each of at least one of the speech segments with the determined number greater than 1: performing speech separation on the each of at least one of the speech segments to obtain multiple audio segments; performing speech recognition on each of the audio segments to obtain respective first speech recognition results for the audio segments; performing feature extraction on each of the audio segments to obtain respective voiceprint feature vectors; and performing clustering on the audio segments with respect to the speakers to obtain a clustering result; and obtaining a second speech recognition result for the speech data based on the clustering result and the respective first speech recognition results.

Abstract: Methods, systems, compositions and strategies for the delivery of WW domain-containing fusion proteins into cells in vivo, ex vivo, or in vitro via ARMMs are provided. Methods, systems, compositions and strategies for the delivery of Cas9 proteins and/or Cas9 variants into cells in vivo, ex vivo, or in vitro via fusion to ARMM associated proteins (e.g., ARRDC1 or TSG101) are also provided.

Abstract: The present disclosure provides a domain dictionary constructing method and apparatus, the method including: segmenting a domain corpus sample to obtain a first character segment set, where the first character segment set includes at least one first character segment; calculating an inter-character correlation index of the at least one first character segment; determining a second character segment set according to the correlation index, where the second character segment set includes a first character segment of which the correlation index is greater than or equal to a preset threshold; determining a third character segment set according to the second character segment set, where the third character segment set includes the second character segment set and second character segments of the domain corpus; constructing a domain dictionary according to the third character segment set.

Abstract: Methods, systems, compositions and strategies for the delivery of RNA into cells in vivo, ex vivo, or in vitro via ARMMs are provided. In some aspects, ARMMs containing fusion proteins of ARRDC1 fused to an RNA binding protein or an RNA binding protein fused to a WW domain are provided. In some aspects, ARMMs containing binding RNAs associated with cargo RNAs are provided. In other aspects, cargo RNAs associated with a binding RNA, such as a TAR element, are loaded into ARMMs via ARRDC1 fusion proteins containing an RNA binding protein, such as trans-activator of transcription (Tat) protein.

Abstract: Disclosed herein are methods, systems, compositions and strategies for the creation and use WW-domain-Activated Extracellular Vesicles, or WAEVs. These WAEVs can be harnessed to deliver and present viral or bacterial antigens useful for vaccine development; to display homing molecules for targeted delivery of therapeutic molecules to specific cells or tissues; and for packaging and delivery of therapeutic molecules via interactions with the WW domains.

Abstract: Disclosed herein are methods, systems, compositions and strategies for the creation and use WW-domain-Activated Extracellular Vesicles, or WAEVs for presenting SARS-CoV-2 antigen domains, for example the SARS-CoV-2 M protein, the SARS-CoV-2 E protein, or the SARS-CoV-2 S protein. These WAEVs can be harnessed to deliver and present SARS-CoV-2 antigens useful for vaccine development.

Abstract: Disclosed herein are methods, systems, compositions and strategies for the creation and use WW-domain-Activated Extracellular Vesicles (WAEVs) for presenting HIV antigen domains. These WAEVs can be harnessed to deliver and present HIV antigens useful for vaccine development. Specifically, the disclosure provides a fusion protein comprising: (a) a WW-containing domain; (b) a transmembrane domain; and (c) an extracellular domain, wherein the extracellular domain is an HIV antigen domain. Further provided are sequences of each domain as well as methods of producing and using the fusion protein.

Abstract: Methods, systems, compositions and strategies for the delivery of WW domain-containing fusion proteins into cells in vivo, ex vivo, or in vitro via ARMMs are provided. Methods, systems, compositions and strategies for the delivery of Cas9 proteins and/or Cas9 variants into cells in vivo, ex vivo, or in vitro via fusion to ARMM associated proteins (e.g., ARRDC1 or TSG101) are also provided.

Abstract: Methods, systems, compositions and strategies for the delivery of RNA into cells in vivo, ex vivo, or in vitro via ARMMs are provided. In some aspects, ARMMs containing fusion proteins of ARRDC1 fused to an RNA binding protein or an RNA binding protein fused to a WW domain are provided. In some aspects, ARMMs containing binding RNAs associated with cargo RNAs are provided. In other aspects, cargo RNAs associated with a binding RNA, such as a TAR element, are loaded into ARMMs via ARRDC1 fusion proteins containing an RNA binding protein, such as trans-activator of transcription (Tat) protein.

Abstract: Methods, systems, compositions and strategies for the use of ARMM-mediated delivery of molecules (e.g., biological molecules, small molecules, proteins, and nucleic acids (e.g., DNA, RNA), DNA plasmids shRNA, mRNA) to cells of the nervous system (e.g., central nervous system and peripheral nervous system).

Abstract: Disclosed herein are minimal arrestin domain containing protein 1 (ARRDC1) constructs, which drive the formation of ARRDC1-mediated microvesicles (ARMMs). These vesicles can be harnessed to package and deliver a variety of molecular cargos such as small molecules, nucleic acids, and proteins. An example of such cargo is the genome editor Cas9.

Abstract: The invention provide isolated arrestin domain-containing protein 1 (ARRDC1)-mediated microvesicles (ARMMs). Methods for generating and for isolating ARMMs are also provided herein. ARMMs can be used to deliver agents, for example, nucleic acids (e.g., siRNAs, microRNAs, lincRNAs), proteins (e.g., transcription factors, chromatin modulators, kinases, phosphorylases, or recombinases), or small molecules to target cells in vitro and in vivo, and methods for such ARMM-mediated delivery are provided herein. Diagnostic and therapeutic methods using ARMMs are also described herein.

Abstract: Methods, systems, compositions and strategies for the delivery of WW domain-containing fusion proteins into cells in vivo, ex vivo, or in vitro via ARMMs are provided. Methods, systems, compositions and strategies for the delivery of Cas9 proteins and/or Cas9 variants into cells in vivo, ex vivo, or in vitro via fusion to ARMM associated proteins (e.g., ARRDC1 or TSG101) are also provided.